NEW YORK (GenomeWeb News) – Provista Life Sciences said today that International Health Technology will offer its early-stage breast cancer detection test in the United Kingdom and in Ireland.
 
Under the license agreement, IHT will offer the blood-based Biomarker Translation Test in its BreastHealth UK clinic this summer. The company said it plans to expand the availability of the test to other European Union countries sometime later, but did not provide further details on its timeline.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.